Article
Biochemistry & Molecular Biology
Ze-Zhong Yu, Bu-Qing Xu, Ying-Ying Wang, Peng-Wei Zhang, Yu-Bin Shu, Zhi Shi
Summary: ABCG2 overexpression leads to multidrug resistance in colorectal cancer. Finding new inhibitors can be an effective way to overcome drug resistance.
Article
Oncology
Yuqing Wang, Jie Huang, Qiong Wu, Jingjing Zhang, Zhiyuan Ma, Shenglin Ma, Shirong Zhang
Summary: The study compared the sensitivity changes of lung adenocarcinoma cells to conventional chemotherapeutic drugs under radioresistant circumstances and found increased toxicities for paclitaxel, docetaxel, and SN-38 in radioresistant cells. The downregulation of the efflux transporter BCRP by long-term fractionated irradiation was identified as a key factor contributing to the increased cytotoxicity of SN-38. These results suggest that irinotecan (the prodrug of SN-38) could be a promising drug candidate for lung adenocarcinoma patients with acquired radioresistance.
INVESTIGATIONAL NEW DRUGS
(2021)
Article
Biochemistry & Molecular Biology
Silpa Narayanan, Nehaben A. Gujarati, Jing-Quan Wang, Zhuo-Xun Wu, Jagadish Koya, Qingbin Cui, Vijaya L. Korlipara, Charles R. Ashby, Zhe-Sheng Chen
Summary: The study showed that the novel benzamide derivative VKNG-2 can reverse MDR caused by overexpression of ABCG2 transporter in colon cancer cells; VKNG-2 significantly improves the efficacy of anticancer drugs in vitro and works by inhibiting the efflux function of the ABCG2 transporter.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Pharmacology & Pharmacy
Samiksha Kukal, Shivangi Bora, Neha Kanojia, Pooja Singh, Priyanka Rani Paul, Chitra Rawat, Shakti Sagar, Naveen Kumar Bhatraju, Gurpreet Kaur Grewal, Anju Singh, Shrikant Kukreti, Kapaettu Satyamoorthy, Ritushree Kukreti
Summary: Despite progress in developing new antiepileptic drugs, poor response to therapy remains a concern. Overexpression of multidrug transporters at the blood-brain barrier is a promising hypothesis explaining treatment failure. This study explores the effect of commonly prescribed AEDs on multidrug transporters in human brain endothelial cells and identifies a potential molecular target to prevent pharmacoresistance.
MOLECULAR PHARMACOLOGY
(2023)
Article
Neurosciences
Yu Zhao, Chuanling Wang, Wenbo He, Zhiyou Cai
Summary: Minocycline mitigates Alzheimer's-like pathology by limiting the activation of the Cdk5/p25 signaling pathway and improves cognitive deficits.
CURRENT NEUROPHARMACOLOGY
(2022)
Article
Biochemical Research Methods
Zahra Rezaei Harandi, Razieh Heidari, Somayeh Reiisi
Summary: The study focuses on co-loading silymarin and metformin into mesoporous silica nanoparticles and evaluating their synergistic effect on the chemotherapeutic efficiency against breast cancer cells. The results show that nano-silymarin enhances the anti-cancer effects against breast cancer cells.
IEEE TRANSACTIONS ON NANOBIOSCIENCE
(2023)
Article
Anatomy & Morphology
Yanhong Mi, Xiaoxiao Xie, Zhongkun Bao, Xiaoyu Xiong, Xinhong Wang, Hongxi Zhang
Summary: The study aimed to investigate the protective effect of dimethyl fumarate (DMF) on necrotizing enterocolitis (NEC) and its mechanism. Results showed that DMF attenuated NEC-induced weight loss and abdominal distension diarrhea, alleviated intestinal pathological injuries, and inhibited intestinal cell apoptosis. These effects were related to the inhibition of the TLR signaling pathway and alleviation of the inflammatory response.
Article
Medicine, Research & Experimental
Ray Sagawa, Seiji Sakata, Bo Gong, Yosuke Seto, Ai Takemoto, Satoshi Takagi, Hironori Ninomiya, Noriko Yanagitani, Masayuki Nakao, Mingyon Mun, Ken Uchibori, Makoto Nishio, Yasunari Miyazaki, Yuichi Shiraishi, Seishi Ogawa, Keisuke Kataoka, Naoya Fujita, Kengo Takeuchi, Ryohei Katayama
Summary: Immune checkpoint therapy targeting the PD-1/PD-L1 axis is a potentially novel development in anticancer therapy. However, there are still some problems, including low response rate, resistance against immune checkpoint blockades, and the lack of reliable biomarkers. This study shows that a splicing variant of PD-L1, PD-L1-vInt4, acts as a decoy in anti-PD-L1 antibody treatment, contributing to the resistance of cancer to therapy.
Article
Oncology
Ai Takemoto, Satoshi Takagi, Takao Ukaji, Nobuhiko Gyobu, Mamoru Kakino, Miho Takami, Asami Kobayashi, Marie Lebel, Tokuichi Kawaguchi, Minoru Sugawara, Kazue Tsuji-Takayama, Kenji Ichihara, Yuki Funauchi, Keisuke Ae, Seiichi Matsumoto, Yoshiya Sugiura, Kengo Takeuchi, Tetsuo Noda, Ryohei Katayama, Naoya Fujita
Summary: In this study, a neutralizing antibody targeting PDPN was developed and showed significant suppression on the growth and metastasis of osteosarcoma. Further analysis revealed the growth signaling pathway involved in the interaction between PDPN and CLEC-2. These findings suggest that neutralizing antibodies could be a novel strategy for treating PDPN-positive osteosarcoma.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Yuki Shimizu, Koutaroh Okada, Jun Adachi, Yuichi Abe, Ryohei Narumi, Ken Uchibori, Noriko Yanagitani, Sumie Koike, Satoshi Takagi, Makoto Nishio, Naoya Fujita, Ryohei Katayama
Summary: This study found that glycogen synthase kinase 3 (GSK3) plays a crucial role in both intermediate and acquired resistance to lorlatinib in ALK-positive NSCLC. Inhibiting GSK3 can suppress the growth of resistant cells and make other resistant cells sensitive to lorlatinib.
NPJ PRECISION ONCOLOGY
(2022)
Article
Oncology
Takuya Sakashita, Noriko Yanagitani, Sumie Koike, Siew-Kee Low, Satoshi Takagi, Satoko Baba, Kengo Takeuchi, Makoto Nishio, Naoya Fujita, Ryohei Katayama
Summary: This study explores the mechanisms of ceritinib resistance in ALK-rearranged NSCLC cells. The researchers identified bypass signals mediated by overexpression and activation of FGFR3 as a mechanism of ceritinib resistance. They also found that amplification of cMET can counteractivate EGFR and/or Her3, leading to ceritinib resistance. Inhibition of FGFR3 and cMET resensitizes the resistant cells to ceritinib. These findings provide insights into potential strategies to overcome ceritinib resistance.
Article
Oncology
Katsutoshi Seto, Junichi Shimizu, Katsuhiro Masago, Mitsugu Araki, Ryohei Katayama, Yukari Sagae, Shiro Fujita, Yoshitsugu Horio, Eiichi Sasaki, Hiroaki Kuroda, Kenichi Okubo, Yasushi Okuno, Toyoaki Hida
Summary: In this study, the sensitivity of BRAF tyrosine kinase inhibitor mechanism in patients with rare BRAF compound mutation was clarified and predicted using genetic analysis and computational simulation model. The results demonstrated the importance of constructing a genomic and simulation fused database for the development of personalized medicine in this field.
Article
Oncology
Yuki Shimizu, Kohei Maruyama, Mai Suzuki, Hiroshi Kawachi, Siew-Kee Low, Tomoko Oh-hara, Kengo Takeuchi, Naoya Fujita, Satoshi Nagayama, Ryohei Katayama
Summary: This study found that BRAF splicing variants activate the RAF/MEK/ERK pathway in BRAF V600E mutation-positive colorectal neuroendocrine carcinomas (CRC-NECs) and contribute to resistance against BRAF inhibitors. MEK or ERK may be potential therapeutic targets to overcome BRAF resistance in CRC-NECs.
Article
Oncology
Yuki Katayama, Tadaaki Yamada, Keiko Tanimura, Shinsaku Tokuda, Kenji Morimoto, Soichi Hirai, Yohei Matsui, Ryota Nakamura, Masaki Ishida, Hayato Kawachi, Kazue Yoneda, Kazutaka Hosoya, Takahiro Tsuji, Hiroaki Ozasa, Akihiro Yoshimura, Masahiro Iwasaku, Young Hak Kim, Mano Horinaka, Toshiyuki Sakai, Takahiro Utsumi, Shinsuke Shiotsu, Takayuki Takeda, Ryohei Katayama, Koichi Takayama
Summary: In this study, it was found that epidermal growth factor receptor (EGFR) signaling is involved in adaptive resistance to lorlatinib in ALK-rearranged NSCLC. EGFR inhibition enhanced ALK inhibition-induced apoptosis and halted the proliferation of ALK-rearranged lung cancer cells. Combination therapy with EGFR inhibitor and lorlatinib significantly suppressed tumor regrowth after cessation of treatment. This study provides new insights into tumor evolution and the development of combined therapeutic strategies for ALK-rearranged lung cancer.
NPJ PRECISION ONCOLOGY
(2023)
Article
Oncology
Mizuki Haraguchi, Kazuma Kiyotani, Tomohiro Tate, Seiji Sakata, Ray Sagawa, Satoshi Takagi, Satoshi Nagayama, Kengo Takeuchi, Kazuhisa Takahashi, Ryohei Katayama
Summary: Immune checkpoint inhibitors (ICIs) have shown significant clinical responses and improved overall survival for various cancers. However, response to ICI therapy varies among patients. This study established a mouse model to better understand the host immune response to tumors and the role of T cells in ICI therapy. The study also identified shared T cell receptors (TCR) in colorectal cancer (CRC) patients. The results suggest that memory T cells play a crucial role in the immune response to tumors and the established model has potential for studying systemic memory T cell behavior.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Meeting Abstract
Oncology
Mai Suzuki, Yuki Shimizu, Kohei Maruyama, Tomoko Ohhara, Naoya Fujita, Satoshi Nagayama, Ryohei Katayama
Meeting Abstract
Oncology
Satoshi Takagi, Sumie Koike, Ai Takemoto, Minoru Sugawara, Naoya Fujita, Ryohei Katayama
Meeting Abstract
Oncology
Yuki Takahashi, Yuki Shimizu, Shiro Kitano, Satoshi Nagayama, Ryohei Katayama, Naoya Fujita
Meeting Abstract
Oncology
Keiko Tanimura, Tadaaki Yamada, Kazue Yoneda, Mano Horinaka, Toshiyuki Sakai, Hisanori Uehara, Seiji Yano, Ryohei Katayama
Meeting Abstract
Oncology
Ryohei Katayama, Naoya Fujita
Meeting Abstract
Oncology
Kohei Maruyama, Yuki Shimizu, Mai Suzuki, Tomoko Ohhara, Naoya Fujita, Satoshi Nagayama, Ryohei Katayama